Your browser doesn't support javascript.
loading
Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma.
Abramson, Jeremy S; Stuver, Robert; Herrera, Alex; Patterson, Emily; Wen, Yi-Ping; Moskowitz, Alison.
Afiliación
  • Abramson JS; Massachusetts General Hospital, Boston, MA, United States. Electronic address: jabramson@mgh.harvard.edu.
  • Stuver R; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Herrera A; City of Hope, Duarte, CA, United States.
  • Patterson E; Massachusetts General Hospital, Boston, MA, United States.
  • Wen YP; City of Hope, Duarte, CA, United States.
  • Moskowitz A; Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Crit Rev Oncol Hematol ; 204: 104499, 2024 Sep 06.
Article en En | MEDLINE | ID: mdl-39244180
ABSTRACT
The ECHELON-1 trial demonstrated the effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment regimen in classical Hodgkin lymphoma. However, peripheral neuropathy (PN) is common with this regimen, occurring in up to two-thirds of patients. While standard prescribing information recommends BV dose modification at the onset of grade 2 PN, management strategies for PN are not well-defined. Most commonly, clinicians dose reduce or discontinue BV, vinblastine, or both. We review evidence-based and practical approaches for managing peripheral neuropathy, emphasizing early detection and dose modification.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos